Employees: 2,400
Size Varex Imaging (VREX) is a United States Health Care company (Medical Specialties) with a market value of $771M, the 2397th largest of 3,085 United States companies the cockpit tracks. Shares closed at $18.15 on 18 Nov 2026.
Performance Over six months the shares gained 79.2%, against -17.5% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 5.3% over the last twelve months (peer median +12.6%); the operating margin is 8.3% (peer median 12.8%).
Valuation It trades at 19.9× forward earnings against a peer median of 20.0× (7th cheapest of 14).
Capital Return on invested capital runs 1.6 points below its cost of capital (8.7% WACC).
Short interest Short interest is 4.8% of the free float (30 Oct 2026).
Next results Next results expected around 24 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $865M | $845M | $811M | $893M | $859M |
| Revenue growth | — | +4% | -9% | +4% | — |
| Gross profit | $297M | $290M | $257M | $290M | $284M |
| EBITDA | $99.5M | $93.3M | $63.2M | $110M | $124M |
| Net income | $22.1M | -$70.3M | -$48.8M | $48.2M | $30.3M |
| Free cash flow | -$20.2M | $17.6M | $18.1M | $87.7M | -$4.40M |
| Capital expenditure | $31.5M | $22.9M | $26.9M | $20.7M | $21.3M |
| Total debt | $379M | $402M | $477M | $470M | $437M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VREX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.4% | -8.5% | 7th highest of 21 |
| 6-month return | +79.2% | -17.5% | 2nd highest of 21 |
| Distance from 52-week high | -2.6% | -41.0% | 2nd highest of 21 |
| Revenue growth (TTM) | +5.3% | +12.6% | 7th lowest of 21 |
| Operating margin | 8.3% | 12.8% | 8th lowest of 21 |
| Forward P/E | 19.9× | 20.0× | 7th cheapest of 14 |
| ROIC minus cost of capital | -1.6 pp | -0.6 pp | 11th highest of 21 |
| EV / EBITDA | 10.7× | 14.7× | 3rd cheapest of 9 |
| Net debt / EBITDA | 2.8× | -1.5× | most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Varex Imaging VREX | United States | $771M | +79% | +5% | 8% | 19.9× | n/a | n/a |
| LifeTech Scientific 1302.HK | Hong Kong | $771M | -30% | +1% | 12% | 19.8× | 9.6% | +15.5% |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $768M | -16% | +39% | 25% | 14.4× | 3.8% | +105.8% |
| Cytek Biosciences CTKB | United States | $774M | +57% | +6% | -21% | n/a | n/a | n/a |
| Mesa Laboratories MLAB | United States | $775M | +33% | +2% | 10% | 11.5× | 21.3% | +13.2% |
| Beta Bionics BBNX | United States | $779M | +42% | +44% | -73% | n/a | n/a | n/a |
| Standard Engineering Technology SETL.NS | India | $783M | +168% | +45% | 14% | n/a | n/a | n/a |
| Maccura Biotechnology 300463.SZ | China | $756M | -18% | -1% | -4% | 421.0× | 7.9% | -10.2% |
| Sino Medical Sciences Technology 688108.SS | China | $753M | -41% | +22% | 19% | 60.0× | 27.9% | +9.9% |
| Allmed Medical Products 002950.SZ | China | $747M | -32% | +14% | 8% | n/a | n/a | n/a |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $744M | -3% | +12% | 18% | 16.2× | -1.9% | +11.8% |
| Shanghai Runda Medical Technology 603108.SS | China | $744M | -36% | -12% | -2% | 20.5× | 20.3% | -0.2% |
| InMode INMD | United States | $741M | -8% | +2% | 18% | 9.8× | -10.8% | +12.4% |
| Beijing Aerospace Changfeng 600855.SS | China | $738M | -44% | -10% | -19% | n/a | n/a | n/a |
| BMC Medical 301367.SZ | China | $737M | -17% | +37% | 17% | 18.7× | -1.5% | +15.6% |
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $736M | -37% | +39% | 24% | 27.4× | 17.1% | +24.2% |
| Seegene 096530.KS | South Korea | $808M | -26% | +13% | 13% | 20.0× | -6.7% | -15.9% |
| Advanced Medical Solutions AMS.L | United Kingdom | $811M | +27% | +6% | 12% | 20.7× | 20.0% | +21.4% |
| MedCap MCAP.ST | Sweden | $811M | -4% | +17% | 15% | 25.8× | 2.7% | +20.9% |
| Beijing Hotgen Biotech 688068.SS | China | $815M | -37% | +8% | -94% | n/a | n/a | n/a |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $818M | -36% | +36% | 16% | n/a | 35.6% | +17.1% |